Daniel Woods, MD
Family Medicine · Savanna, ILNPI 1942276159
Payments from drug & device makers
Across 302 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$897
- Amgen$814
- GSK$399
- Pfizer$359
- Boehringer Ingelheim$310
- Johnson & Johnson$243
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,36599%
- Other$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $897 |
| Amgen | 46 | $814 |
| GSK | 24 | $399 |
| Pfizer | 26 | $359 |
| Boehringer Ingelheim | 18 | $310 |
| Johnson & Johnson | 16 | $243 |
| Catalyst Orthoscience | 3 | $236 |
| Novo Nordisk | 13 | $223 |
| E.r. Squibb & Sons, L.L.C. | 10 | $199 |
| AbbVie(2 entities) | 9 | $174 |
| Bayer | 10 | $165 |
| Lilly USA, LLC | 10 | $153 |
| Merck | 9 | $140 |
| Novartis | 8 | $126 |
| Abbott | 4 | $98 |
| Exact Sciences | 5 | $93 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Corcept Therapeutics | 4 | $81 |
| Kowa Pharmaceuticals America, Inc. | 5 | $78 |
| Astellas Pharma US Inc | 5 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Dexcom, Inc. | 3 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Lundbeck LLC | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Acadia Pharmaceuticals Inc | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,415 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 214 | $267,351 |
| FarxigaDapagliflozin Propanediol | 463 | $252,494 |
| EliquisApixaban | 391 | $241,421 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 298 | $231,608 |
| XareltoRivaroxaban | 237 | $175,400 |
| JardianceEmpagliflozin | 272 | $164,545 |
| JanuviaSitagliptin Phosphate | 152 | $111,534 |
| OzempicSemaglutide | 103 | $99,844 |
| Repatha SureclickEvolocumab | 84 | $65,165 |
| MyrbetriqMirabegron | 125 | $58,706 |
| MounjaroTirzepatide | 47 | $52,590 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $44,111 |
| LinzessLinaclotide | 32 | $34,964 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 29 | $33,298 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $32,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $223 | $367,195317 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $897 | $283,929525 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy | $399 | $278,602443 claims |
| PfizerEliquis, Abrysvo, Premarin | $359 | $275,625511 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $310 | $187,713301 claims |
| Johnson & JohnsonXarelto | $243 | $175,400237 claims |
| MerckJanuvia | $140 | $111,534152 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $58,706125 claims |
| Lilly USA, LLCMounjaro | $153 | $52,59047 claims |
| AbbVieLinzess | $174 | $34,96432 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $84 | $19,67230 claims |
| NovartisEntresto | $126 | $14,53225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Savanna
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.